Clinical Trial Update: Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of bicalutamide and abemaciclib for androgen receptor–positive triple-negative breast cancer is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Casodex (bicalutamide)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: RECRUITING